ReviewBiology2026
Beyond the Liver: Brain Rap1 Signaling in Metformin's Antidiabetic Action.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin remains a promising therapeutic drug for type 2 diabetes mellitus (T2DM) due to its glucose-lowering effects through hepatic and other peripheral mechanisms. Recent evidence shows that the brain may represent an additional site of action. The small GTPase Ras-related protein 1 (Rap1), potentially connects central metformin exposure to systemic glucose homeostasis. The current review discusses neuronal Rap1 regulation and a role in metformin's antidiabetic effects. Preclinical findings indicate that excessive neuronal Rap1 activity may contribute to metabolic dysfunction, whereas its inhibition is related to improved glucose regulation. Recent experimental evidence further suggests that low-dose metformin reduces Rap1 activity in the ventromedial hypothalamus (VMH). Moreover, metformin also alters the excitability of steroidogenic factor-1-positive neurons that contributes to its hypoglycemic effect. Initial findings also suggest a functional relationship between Rap1 and AMPK, although the molecular mechanisms showing the mTORC1 connection remain to be clarified. This review also considers how central Rap1 signaling might interact with gut-brain-liver pathways that can affect peripheral metabolism. Human central nervous system (CNS) studies and primary RAP1A pharmacogenetic results offer indirect translational support, but direct evidence of hypothalamic Rap1 involvement in patients is currently not documented. Extending beyond previous reviews of the preclinical VMH-Rap1 mechanism, this review integrates dose-CNS exposure relationships with emerging human evidence, particularly CSF pharmacokinetics and RAP1A pharmacogenetics. These findings provide preliminary translational links, although direct hypothalamic Rap1 engagement in humans remains unproven. Future studies should elucidate circuit-specific mechanisms, determine reliable biomarkers, and assess selective pathway modulation. A better understanding of this relationship may help determine whether brain Rap1 could ultimately serve as a therapeutic target to improve metformin responsiveness in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.